Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer

Author(s): Jing Yu, Liyan Jin, Linhua Jiang, Ling Gao, Jin Zhou, You Hu, Wei Li, Qiaoming Zhi, Xinguo Zhu

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 16 , Issue 4 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Circulating microRNAs are novel and non-invasive tumor biomarkers for colorectal cancer (CRC) detection. In this study, we investigated miR-372 expression in serum and tissues in CRC and colorectal precancerous lesions (CPL) patients by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Our data demonstrated that serum or tissue miR-372 levels were significantly up-regulated in patients with CRC or CPL, compared to healthy control (HC) subjects or normal tissues (P<0.05). High miR-372 expression in early colorectal cancer (ECRC) tissues were statistically significantly associated with tumor size (P<0.05), Tumor-Nodes-Metastasis (TNM) stage (P<0.05), and led to a worse overall survival (P=0.012). Postoperative serum miR-372 levels in ECRC patients significantly dropped, compared to the corresponding preoperative levels (P<0.05). The AUC of serum miR-372 expression for ECRC diagnosis was 0.854, which was significantly higher than that of combined tumor markers (CEA, CA19-9 and CA12-5) (0.613) (P<0.05). The sensitivity and specificity of serum miR-372 expression for ECRC diagnosis were 81.9 % and 73.3 %. All these findings provided an evidence that serum miR-372 could be a noninvasive biomarker for the early detection and prognosis of CRC.

Keywords: Colorectal cancer, diagnosis, miR-372, serum, prognosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 18 February, 2016
Page: [424 - 431]
Pages: 8
DOI: 10.2174/1871520615666150716110406
Price: $65

Article Metrics

PDF: 56
PRC: 1